Navigation Links
Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting

PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today interim results from two ongoing Phase 1 trials in hormone refractory prostate cancer (HRPC) demonstrating dose-dependent T-cell activation and clinical activity of ipilimumab, an investigational anti-CTLA-4 antibody. These studies were done in combination with antigen-releasing immunotherapies based on GM-CSF, a cytokine that stimulates the proliferation of white blood cells and augments immune responses, and results were presented in two separate oral presentations by investigators at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego.

"The interim results demonstrating clinical activity in these ongoing trials lend additional support to the concept of ipilimumab as part of a therapeutic regimen in treating prostate cancer," said Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We will continue to explore the prospects of ipilimumab in HRPC, and we expect further data in prostate cancer for ipilimumab monotherapy and in combination with other antigen-releasing agents at this year's ASCO conference in June."

-- "Dendritic and T cell functions in patients with metastatic

hormone-refractory prostate cancer treated with GVAX immunotherapy for

prostate cancer and ipilimumab" (Abstract #2538)

Interim data from the ongoing Phase 1 study of escalating doses of

ipilimumab in combination with the Cell Genesys, Inc. GVAX

immunotherapy for prostate cancer (an investigational agent comprised

of whole tumor cells modified to secrete GM-CSF) were presented by

Saskia JAM Santegoets, Ph.D., from the Department of Medical Oncology

and Pathology of Vrije Universiteit Medical Center located in

Amsterdam, Netherlands. The data suggested an ipilimumab dose-related

association with increased T-cell activation, as well as associated

anti-tumor activity from the initial 12 patients that was previously

reported at the June 2007 American Society of Clinical Oncology (ASCO)


In the Phase 1 clinical trial, 28 patients with metastatic HRPC have

been enrolled, including 12 patients in the dose-escalation cohort

(0.3, 1, 3 or 5 mg/kg ipilimumab) and 16 patients in the expansion

cohort (3 mg/kg ipilimumab). The dose of GVAX immunotherapy for

prostate cancer used in this combination trial is comparable to that

currently being evaluated in Cell Genesys' ongoing Phase 3 program. The

treatment combination was generally well-tolerated. Adverse events

associated with this regimen are consistent with data previously

reported from this study.

-- "CTLA-4 blockade for hormone refractory prostate cancer: dose-dependent

induction of CD8+ T cell activation and clinical responses" (Abstract


Preliminary data from an ongoing Phase 1 study of escalating doses of

ipilimumab in combination with GM-CSF (sargramostim) were presented by

Lawrence Fong, Ph.D., from the University of California, San Francisco,

San Francisco. Of the six patients treated at 3 mg/kg ipilimumab, three

experienced confirmed decreases in prostate-specific antigen (PSA)

serum levels of over 50%, and one of these patients experienced a

partial response in hepatic metastases.

In the Phase 1 clinical trial, 26 patients with HRPC received treatment

with a 28-day cycle of daily doses of 250 mg/m2 of GM-CSF for 14 days

in combination with ipilimumab administered on the first day of the

28-day cycle for up to four cycles. Ipilimumab dosing initially ranged

from 0.5 mg/kg to 3 mg/kg. Additional patients are now being treated

with higher doses (5 mg/kg and 10 mg/kg) of ipilimumab. The treatment

combination was generally well-tolerated. Adverse events associated

with ipilimumab treatment are consistent with data previously reported

from this study and from other clinical trials of ipilimumab.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein relating to the interim data from ongoing ipilimumab combination Phase 1 studies may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "preliminary"; "interim"; "potential"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):